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OBJECTIVE The purpose of this study was to address the timing of sudden death in advanced heart failure
patients.
BACKGROUND Sudden death is a catastrophic event in cardiovascular disease. It has a circadian pattern
prominent in the early AM, which has been thought to be due to a surge of sympathetic
stimulation. We postulated that the distribution of events in advanced heart failure, with
chronic sympathetic activation, would be more uniform implicating other potential mecha-
nisms.
METHODS We analyzed data from Prospective Randomized Amlodipine Survival Trial (PRAISE).
Sudden deaths were analyzed by time of death in 4-h and 1-h blocks for uniformity of
distribution in the entire cohort, and in the prespecified ischemic and nonischemic stratum.
Further analyses were undertaken in the treatment groups of amlodipine and placebo, and
among those receiving background therapy of aspirin and warfarin.
RESULTS Sudden deaths in the overall cohort showed a nonuniform distribution with a PM peak but not
an AM peak. The ischemic stratum also showed a PM peak, but sudden deaths within the
nonischemic stratum were uniformly distributed. Neither amlodipine treatment nor aspirin or
warfarin use altered the distribution.
CONCLUSIONS Sudden death in advanced heart failure did not show an AM peak, suggesting that circadian
sympathetic activation did not strongly influence these events. The PM peak noted is likely
complex in origin and was not affected by antiischemic or antithrombotic medications. (J Am
Coll Cardiol 2000;36:541–6) © 2000 by the American College of Cardiology
Sudden death occurs in all aspects of cardiovascular disease
and our understanding of these events is limited. Large
population studies have shown a nonuniform circadian
distribution of events with a morning peak (1–3) and a
smaller secondary afternoon peak (1,4). A similar circadian
pattern has been noted with acute myocardial infarction
(5,6), myocardial ischemia (7), out-of-hospital cardiac arrest
(8), ventricular tachycardia post–myocardial infarction (9),
and stroke (10). An explanation, particularly for the early
peak, has been the coincidence of these events with evidence
of activation of trigger factors relating to neurohormonal
activation and thrombosis (2). Therefore, the concept has
developed that neurohormonal activation leads to myocar-
dial infarction, ischemia or lethal arrhythmias that can
culminate in sudden cardiac death.
Sudden death is a major mode of death in patients with
heart failure, varying between 20% and 75% of deaths
depending on the definition and the studied population
(11). However, triggers that might cause sudden death in
heart failure are uncertain in spite of the high prevalence,
and only one study is available on the circadian pattern of
events (12). Because the sympathetic nervous system is
characteristically activated in heart failure, we postulated
that this chronic neurohormonal stimulation would cause a
more uniform distribution of sudden deaths that might aid
in our understanding of these events. Therefore, we retro-
spectively analyzed the timing of sudden death within the
Prospective Randomized Amlodipine Survival Evaluation
(PRAISE) (13) database to assess the distribution of events.
Because the distribution might differ by the presence or
absence of significant ischemic heart disease, we examined
events within the prespecified strata for ischemic or nonisch-
emic groups within PRAISE. Because medications with
antiischemic or antithrombotic effects might also alter the
distribution of events, we analyzed by treatment with the
prospective study medication, amlodipine, as well as with
aspirin and coumadin.
METHODS
Patient population. The PRAISE trial was a randomized,
double-blind, placebo-controlled study of amlodipine versus
placebo treatment of 1,153 patients with advanced heart
failure including left ventricular ejection fraction ,30% and
New York Heart Association (NYHA) class III or IV
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symptoms. Patients on cardiac transplantation lists and
beta-blocker agents were excluded from the study. Patients
who had a history of myocardial infarction, angioplasty,
bypass surgery, significant coronary artery disease or angina
were clinically considered to have an ischemic etiology for
their heart failure. The nonischemic category was used for
all other patients. Other details of the patient population
have been described (13). Patients were stratified by the
etiology of the cardiomyopathy (ischemic or nonischemic)
and then were randomized to receive either amlodipine or
placebo.
End points. The primary end point of the PRAISE trial
was the combined incidence of all-cause mortality or car-
diovascular morbidity (hospitalization for at least 24 h for
the following: sustained ventricular tachycardia or fibrilla-
tion, nonfatal myocardial infarction, pump failure requiring
inotropic support or acute pulmonary edema). The second-
ary end point was all-cause mortality. An eight-member end
point classification committee classified deaths in a cause-
specific analysis using the following definitions. Sudden
death was defined as death from cardiac or unknown causes
that occurred instantaneously or within 60 min of symptom
onset. Patients who were resuscitated from cardiac arrest,
remained comatose and were pronounced dead within 72 h
were classified as sudden deaths. Pump failure death was
defined as progressive pump failure culminating in death,
not associated with myocardial infarction or an observed
sudden life-threatening arrhythmia. Death that occurred
more than 60 min from the onset of symptoms during
hospitalization for a proven myocardial infarction was clas-
sified as a fatal myocardial infarction.
Time of death was ascertained from available data includ-
ing death certification, emergency medical forms, hospital
records and investigator statements. Patients who did not
have a time of death within 4 h were eliminated from
analysis.
Statistical analyses. Baseline variables groups were com-
pared for survivors and for sudden deaths. Statistical com-
parisons are for differences between groups. Circadian
pattern for time of death was analyzed in six 4-h intervals.
For example, a patient found dead at 2 AM and last seen at
10 PM would have 0.25 assigned to each hour in that
interval. The four blocks were then tested for uniformity
using a chi-square analysis. These analyses were undertaken
for the entire cohort of sudden death, ischemic and nonisch-
emic strata, treatment with amlodipine and placebo and
treatment with aspirin or coumadin. Due to concern that
the 4-h interval analysis may have introduced bias, we
analyzed also by 1-h intervals using a chi-square analysis for
uniformity.
RESULTS
Overall, there were 352 deaths among the 1,153 patients in
PRAISE. The Endpoint Classification Committee deter-
mined 185 to be sudden deaths. Patient characteristics for
sudden death and survivor patient groups are seen in Table
1. The survivor patients were less commonly class IV,
ischemic etiology or with a previous history of myocardial
infarction than the patients who died suddenly.
Circadian analysis. Of the 185 sudden death patients, a
time of death could be determined within a 4-h interval in
158 (85.4%) (Fig. 1). Testing for circadian distribution with
a chi-square analysis, using 4-h blocks, indicated a nonuni-
formity (p , 0.01) with a striking peak at the 4 PM to 8 PM
interval (Fig. 1). An early AM peak was not observed.
Analysis of the prespecified ischemic and nonischemic strata
indicated that nonuniformity was present in the ischemic
patients (p , 0.001) with a peak in the 4 PM to 8 PM interval,
but not in the nonischemic group (Fig. 2).
Analysis of events was also undertaken by 1-h intervals.
Abbreviations and Acronyms
ASIST 5 Atenolol Silent Ischemia Study
BHAT 5 Beta Blocker Heart Attack Trial
CASS 5 Coronary Artery Surgery Study
CAST 5 Cardiac Arrhythmia Suppression Trial
PRAISE 5 Prospective Randomized Amlodipine
Survival Evaluation
Table 1. Selective Baseline Characteristics of Survivors and Sudden Death Patients
Measure Alive Sudden Death 1 Post.R
Age (yrs) N 740 162
Mean 64 (23.4–93.7) 64.7 (25.4–93.7)
Cardiothoracic ratio N 680 142
Mean 0.6 (0.2–0.9) 0.6 (0.2–0.9)
LVEF (%) N 740 162
Mean 21.2 (5.0–65.0) 20 (7.0–30.0)
Baseline covariate
Baseline NYHA classification Percent class IV 15.15 27.16
Baseline etiology Percent ischemic 59.19 66.67
History of MI Percent yes 56.35 66.05
History of diabetes Percent yes 35.68 39.51
History of hypertension Percent yes 58.78 53.70
Gender Percent female 26.08 16.67
LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; NYHA 5 New York Heart Association.
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The data are limited by the number of events within each
interval but a trend for nonuniformity was present for the
entire cohort of sudden deaths with a PM peak (p 5 0.08)
(Fig. 3). A similar nonuniform distribution was noted
within the ischemic group (p 5 0.005).
A minority of patients experiencing sudden death had
documented heart rhythm data. For those with ventricular
tachycardia or ventricular fibrillation, nonuniformity was
weakly seen (p 5 0.046) with a PM peak, while a nonuni-
form distribution was not seen for other rhythms (Fig. 4).
Treatment effect. The prospective treatment in PRAISE
was amlodipine, a calcium antagonist with antiischemic
properties. Patients treated with amlodipine showed a
similar distribution of events to the overall cohort in analysis
of 4-h intervals (p 5 0.005). Amlodipine treatment did not
alter the distribution of events either in the entire sudden
death cohort or within the strata. Antithrombotic medica-
tions commonly used in PRAISE were warfarin and aspirin.
Both were associated with the same pattern of nonunifor-
mity in the ischemic strata: warfarin (p 5 0.0002) and
aspirin (p 5 0.03).
DISCUSSION
The current study evaluated the circadian pattern of sudden
death in advanced heart failure patients. The major findings
were that events did not cluster in the AM but did later as a
PM peak. This PM cluster of events was present only in
ischemic cardiomyopathy patients and was not altered with
antiischemic or antithrombotic treatment.
Figure 1. All sudden deaths graphed by 4-h intervals. Analysis includes those with 4-h interval time of death with partial count included for each hour of
the interval.
Figure 2. Sudden death in the ischemic and nonischemic strata with time of death within 4-h intervals.
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Circadian rhythm and myocardial events. The
PRAISE results differ from previous reports that dem-
onstrated a single peak in early morning or a bimodal
distribution of deaths in morning and late afternoon or
evening. In 1987 Muller et al. (1) reported data that
sudden death incidence was highest between 7 AM and 11
AM, while Willich et al. (2) reported a peak between 7 AM
and 9 AM. While both reports were from large unselected
databases, other groups have published data with similar
results in heart failure (12) and in the elderly (14). Of
interest, Arntz et al. (15) reported that while a bimodal
pattern was prominent in those over age 65, older
patients had only a monophasic peak. Therapy also can
alter the pattern. In CAST, Peters et al. (16) noted a
Figure 3. All sudden deaths with time of death within 1-h intervals.
Figure 4. All sudden deaths with a presenting identifiable rhythm. (A) Ventricular tachycardia or fibrillation; (B) other rhythms.
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biphasic pattern in placebo patients but an early AM peak
only in the antiarrhythmic group.
A circadian pattern of myocardial infarction and myocar-
dial ischemia has paralleled the pattern of sudden death and
suggested a possible relation. Muller et al. (4) in 1985
reported a peak of myocardial infarction from 6 AM to 12
noon. Other reports, however, indicate that a bimodal
distribution of events occurs. Hjalmersen et al. (5) reported
a bimodal peak of events for 6 AM to 12 noon and 6 PM to
12 midnight, although only a PM peak in heart failure
patients. Myocardial ischemia has been noted also to follow
a circadian pattern of early AM peak incidence in recent
reports (7,17). Other myocardial events, particularly ven-
tricular tachycardia post–myocardial infarction (9) and out-
of-hospital cardiac arrest (8), have also shown a circadian
distribution. The current study does show a limited circa-
dian pattern for sudden death with ventricular arrhythmic
events but not other rhythms. Similar findings were noted
by Arntz et al. (15) in a nonselected population.
The PRAISE data do conflict with the report of Moser et
al. (12) in which sudden deaths in a heart failure population
peaked between 6 AM and 12 noon. The patient databases
were both that of advanced heart failure. However, the
larger PRAISE population was older (64 vs. 48 years) and
more commonly on a converting enzyme inhibitor (100% vs.
40%) or digitalis (100% vs. 50%). The sudden death
population in PRAISE was also predominantly ischemic
heart failure (63% vs. 43%). Furthermore, the distribution of
events may have been further altered by cardiac transplant in
the Moser study (31% vs. 1.5% in PRAISE). Finally,
methodologic factors such as sudden death definitions or
adjudication may also differ in a single center analysis (such
as Moser et al. [12]) compared with a multicenter trial with
a central end points committee as in PRAISE.
Relation of mechanism. It should be emphasized that
sudden death in heart failure is a topic of great complexity.
While the events are often ascribed to ventricular tachycar-
dia or ventricular fibrillation, Luu et al. (18) demonstrated
that a minority of sudden terminal events were tachyar-
rhythmias. Undiagnosed myocardial infarction is of partic-
ular interest due to the similarity between sudden death and
myocardial infarction circadian events patterns in previous
reports. The finding, in this analysis, that the PM peak is
only present in the ischemic stratum is concordant with
other lines of evidence implicating ischemic events as a
mechanism of sudden death. In non–heart failure popula-
tions, based on the prevalence of coronary thrombus on
autopsy and of proven myocardial infarction in cardiac arrest
survivors, Willich et al. (2) estimated that a third of sudden
deaths in the general population may be due to myocardial
infarction. Retrospective data from CASS (19) in angina
patients and uncontrolled data on cardiac arrest patients
(20,21) also support an ischemic etiology because sudden
death appears to be decreased by coronary bypass revascu-
larization grafting. Further, autopsy data from ATLAS
(22), while likely influenced by selection bias, is intriguing
in showing strong evidence of acute ischemic events among
sudden deaths in ischemic cardiomyopathy patients.
Adrenergic activation has been a suspected trigger for
sudden deaths and ischemic events because the AM peak
corresponds to the time in which awakening most com-
monly occurs. This awakening prompts increased sympa-
thetic activation, which in turn affects heart rate, vasoactiv-
ity and the clotting cascade, which then could precipitate
ischemic episodes (23–27).
While the direct relation of ischemic triggers to cardio-
vascular events remains somewhat speculative, agents that
effect them have altered the circadian distribution of events.
Beta-blocker therapy has been noted to decrease the morn-
ing peak of myocardial ischemia in ASIST (28) and of
sudden deaths in BHAT (29). Parker et al. (30) also noted
that beta-blockers decreased episodes of ischemia associated
with awakening and physical activity. Curiously, PM epi-
sodes were less likely to involve heart rate rises and were less
influenced by beta-blockade. Aspirin therapy has also been
associated with a decrease in morning myocardial infarction
presumably by its effect on platelet aggregabitity (6).
The role for an adrenergic trigger in heart failure as an
explanation for a circadian rhythm of events is more
difficult. Advanced heart failure patients have chronically
elevated catecholamines levels (31), which are at once both
markers for disease severity as well as toxic substances (32).
The sustained catecholamine levels produce deception
downregulation and desensitization (33). Furthermore,
while direct measurements of circadian sympathetic activa-
tion are lacking, indirect measurement such as heart rate
variability indicates little change in low-frequency oscilla-
tions that are influenced by change in sympathetic tone in
heart failure (34). Heart failure patients would then be less
likely to have heart rate–driven ischemic events, such as
those described by Parker et al. (30) because heart rate
would likely change little and episodic adrenergically driven
events would be rare. A chronically stimulated adrenergic
state would then cause a uniformly increased risk for events.
Hence, the lack of an early morning peak is unsurprising.
Other populations, where the effect of an alteration in
sympathetic time is blunted such as diabetics with severe
autonomic dysfunction (35), or patients on a beta-blocker
(29), also lack a morning peak.
The late afternoon peak found in the current study has no
clear explanation, but the finding that the PM circadian
pattern is only present in the ischemic stratum raises the
possibility that some portion of these events could be
ischemic. However, in PRAISE, medications with antiisch-
emic properties such as amlodipine or antithrombotic prop-
erties such as aspirin or warfarin did not alter the distribu-
tion of events. Previously Ridker et al. (6), with aspirin, and
Parker et al. (30), with beta-blockers, had also shown no
effect on the PM peak, suggesting that this phenomena may
be a complex interaction between multiple factors leading to
sudden death.
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Limitations. The current analysis was a retrospective anal-
ysis within the PRAISE database. As discussed above, the
assessment of sudden death is complex and often indicates a
mode rather than a specific mechanism. The PRAISE end
points committee carefully adjudicated deaths using con-
ventional prospective definitions similar to other trials. The
time of death could be estimated to within 4 h in 82% of
sudden death patients, which compares favorably with other
study populations: CAST 78% (16) and Moser 75% (12).
This analysis does not contain data on time of awakening.
However, Peters et al. (16) noted little relation of awakening
to events in the CAST placebo group and the persistence of
the PM peak even when adjusted for weakening peak.
Clinical implications. The circadian analysis from
PRAISE does not support the finding in other populations
of an AM peak of sudden deaths. The episodic sympathetic
activation in other populations that do not have chronic
adrenergic stimulation may not be relevant in heart failure
patients. The PM peak was not altered by antiischemic or
antithrombotic agents and therefore may be a complex
interaction of risk factors. Because heart failure patients die
suddenly in nearly half of fatal events, further analysis is
needed to assess this crucial area.
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